{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"73"},{"groupId":"OG002","value":"32"}]}],"title":"Number with frozen tumor tissue"},{"categories":[{"measurements":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"153"},{"groupId":"OG002","value":"71"}]}],"title":"Number with fixed tumor tissue"}],"denoms":[{"counts":[{"groupId":"OG000","value":"57"},{"groupId":"OG001","value":"156"},{"groupId":"OG002","value":"77"}],"units":"Participants"}],"description":"Successful collections will be defined as the number of patients who have frozen/fixed tumor samples available.","groups":[{"description":"Patients with gross total resection (GTR)/no evidence of metastatic disease (M0) medulloblastoma, nodular desmoplastic or high grade glioma histology will receive induction chemotherapy and low-risk therapy.","id":"OG000","title":"Low-Risk Group"},{"description":"Patients with (M0) medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease, will receive induction chemotherapy and intermediate-risk therapy.","id":"OG001","title":"Intermediate-Risk Group"},{"description":"Patients with central nervous system (CNS) metastatic disease will receive induction chemotherapy and high-risk therapy.","id":"OG002","title":"High-Risk Group"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All eligible patients enrolled (n=290) were included in this analysis. The numbers of patients with pre-study samples were considered for these results.","reportingStatus":"POSTED","timeFrame":"Based on samples obtained at the time of initial surgery or repeat surgery prior to treatment","title":"Number of Successful Collections for Frozen and Fixed Tumor Samples","type":"SECONDARY","unitOfMeasure":"Participants"}